Public CompanyGSK to launch 'promecta' in India by 2009-end
Glaxo SmithKline Pharmaceutical today said it is looking at launching its patented medicine promecta, used in treatment of depleted platelet count, in India by this year-end or early next year.
- Aurobindo Pharma receives Swissmedic approval for cefepime for injection - Ranbaxy receives final USFDA approval for Glycopyrolate - SC pulls up Ranbaxy for delayed raising of refund issue - Sun Pharma invalidates Eli Lilly"s Gemzar patent - Glenmark"s drug fails clinical trials - Aurobindo Pharma to acquire Trident Life Sciences
"We are looking to launch our promecta in the Indian market in the fourth quarter of this year or in the first quarter of next year," GSK Vice President South Asia and Managing Director India Hasit Joshipura told reporters on the sidelines of a function here.
When asked if the company has got drug regulator DCGI nod for launching the medicine here, he said, "We have applied for the regulatory approval but we haven"t got it yet. But we hope to get it by the end of this year of early next year."